Shanghai Argo Biopharmaceutical

Privately held: no public share price

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 2
ANGPTL3RNA / oligonucleotide
Cardiovascular Disease / Dyslipidemia
Hypertriglyceridemia
Phase 2
Lipoprotein(a) [Lp(a)] production pathwayRNA / oligonucleotide
Atherosclerotic Cardiovascular Disease

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
April 2027 (1)
BW-20829Phase 2Lipoprotein Disorder
Est. primary completion 2027-04-26 · NCT07235046 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.